Pulmatrix Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases
The company utilizes its proprietary technology platform to create new treatments that target and modulate the underlying mechanisms of respiratory conditions, including chronic obstructive pulmonary disease (COPD) and asthma. Pulmatrix aims to improve the lives of patients through the development of novel inhaled therapeutics that enhance drug delivery and optimize treatment outcomes. With a commitment to advancing respiratory health, Pulmatrix is dedicated to bringing transformative solutions from the laboratory to the patients who need them.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pulmatrix, Inc. (NASDAQPULM) and Cullgen Inc. is fair to Pulmatrix shareholders. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company.
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix, Inc. (NasdaqCM: PULM) and Cullgen Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Pulmatrix shareholders.
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Ademi LLP is investigating Pulmatrix (Nasdaq: PULM) for possible breaches of fiduciary duty and other violations of law in its transaction with Cullgen.
BALA CYNWYD, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pulmatrix, Inc. (NASDAQPULM) and Cullgen Inc. is fair to Pulmatrix shareholders. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company.
Gainers Spero Therapeutics (NASDAQSPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million.
Pulmatrix (NASDAQPULM) has dosed first subject in its Phase 1 trial evaluating PUR3100 for the treatment of acute migraine. PUR3100 is an orally-inhaled Dihydroergotamine (DHE) acute migraine therapy.
